Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7373
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1 ; volume:147 ; number:3 ; day:19 ; month:3 ; year:2020 ; pages:557-566 ; date:5.2020
Journal of neuro-oncology ; 147, Heft 3 (19.3.2020), 557-566, 5.2020
- Urheber
-
Gallitto, Matthew
Cheng He, Rossana
Inocencio, Julio F.
Wang, Huaien
Zhang, Yizhou
Deikus, Gintaras
Wasserman, Isaac
Strahl, Maya
Smith, Melissa
Sebra, Robert
Yong, Raymund L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-020-03461-4
- URN
-
urn:nbn:de:101:1-2020080123420640005705
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gallitto, Matthew
- Cheng He, Rossana
- Inocencio, Julio F.
- Wang, Huaien
- Zhang, Yizhou
- Deikus, Gintaras
- Wasserman, Isaac
- Strahl, Maya
- Smith, Melissa
- Sebra, Robert
- Yong, Raymund L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide